A TCGA lower-grade glioma study used comprehensive multiple omics data and unbiased integrative bioinformatics analyses to define three molecular subtypes based on two molecular markers, 1p/19q codeletion and IDH1/2 mutations (110). This evidence concerns the gene IDH1 and central nervous system cancer.